...
首页> 外文期刊>International journal of infectious diseases : >Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences
【24h】

Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences

机译:尽管持续使用皮质类固醇和甲氨蝶呤以及可能的免疫后果,但仍具有有利的结果,具有良好的结果,具有良好的结果,具有良好的结果。

获取原文
           

摘要

Type 2 leprosy reaction (T2LR), or Erythema Nodosum Leprosum (ENL), often poses a therapeutic challenge to clinicians and commonly requires long courses of steroids for control. While immunosuppressants are known to achieve control and lower steroid dependence in T2LR, the prospect of managing a severe T2LR in conjunction with COVID-19, with the concern of worsening COVID-19 with long-term immunosuppression has not previously been encountered. We report a case of severe T2LR treated with oral steroids and methotrexate, with COVID-19 infection acquired during hospital stay, and a favourable outcome achieved despite the continued use of immunosuppressants. We discuss the possible reasons for this both in terms of the drug pharmacodynamics and the immunological profile of T2LR.
机译:2型麻黄反应(T2LR),或红斑核心麻风病(ELO),经常对临床医生构成治疗挑战,通常需要长期的类固醇疗程进行控制。 虽然已知免疫抑制剂在T2LR中实现对照和更低的类固醇依赖性,但先前没有先前遇到与Covid-19一起管理严重T2LR的前景,并未涉及具有长期免疫抑制的Covid-19的关注。 我们举报了用口腔类固醇和甲氨蝶呤治疗的严重T2LR的病例,并且在住院期间收购的Covid-19感染,尽管持续使用免疫抑制剂,但仍有良好的结果。 我们在药物药效学和T2LR的免疫学特征方面讨论了这一切的可能原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号